Early versus delayed post-therapy whole body scintigraphy for well-differentiated thyroid carcinoma: A meta-analysis

Introduction@#No clear consensus exists as to the optimal timing for conducting whole body scintigraphy (WBS) after radioactive iodine (RAI) therapy for differentiated thyroid carcinoma. @*Objective@#This study aimed to compare the utility of early versus delayed post-therapy WBS in identifying residual lesions and metastases.@*Methods@#A systematic review of existing literature was done, yielding 6 observational studies relevant to the subject. Meta-analyses were done comparing lesion detecting rates of early (3-4 days post-RAI) and delayed (7-11 days post-RAI) post-therapy WBS for thyroid remnants and metastases in the lymph nodes, lungs, and bone using a random-effects model with odds ratios (OR) and 95% confidence intervals (CIs). A subgroup analysis was also done relating to the type of collimator used in imaging.

Analysis of risk factors for recurrence of differentiated thyroid carcinoma after surgical resection combined with iodine-131 and TSH suppression therapy / 临床耳鼻咽喉头颈外科杂志

Objective:To investigate the risk factors of recurrence after surgical resection of differentiated thyroid carcinoma combined with iodine-131 and TSH（Thyroid stimulating hormone） inhibition therapy. Methods:From January 2015 to April 2020, the clinical data of patients with structural recurrence and without recurrence were retrospectively collected after surgical treatment combined with iodine-131 and TSH inhibition therapy in the First Medical Center of PLA General Hospital. The general conditions of the two groups of patients were analyzed and the measurement data in line with the normal distribution was used for comparison between groups. For measurement data with non-normal distribution, the rank sum test was used for inter-group comparison. The Chi-square test was used for comparison between the counting data groups. Univariate and multivariate regression analyses were used to determine the risk factors associated with relapse. Results:The median follow-up period was 43 months（range 18-81 months） and 100 patients（10.5%） relapsed among the 955 patients. Univariate analysis showed that tumor size, tumor multiple, the number of lymph node metastases>5 in the central region of the neck, and the number of lymph node metastases>5 in the lateral region were significantly correlated with post-treatment recurrence（P<0.001, P=0.018, P<0.001, P<0.001）. Multivariate analysis showed that tumor size（adjusted odds ratio OR: 1.496, 95%CI: 1.226-1.826, P<0.001）, tumor frequency（adjusted odds ratio OR: 1.927, 95%CI: 1.003-3.701, P=0.049）, the number of lymph node metastases in the central neck region>5（adjusted odds ratio OR: 2.630, 95%CI: 1.509-4.584, P=0.001） and the number of lymph node metastases in the lateral neck region>5（adjusted odds ratio OR: 3.074, 95%CI: 1.649-5.730, P=0.001） was associated with tumor recurrence. Conclusion:The study showed that tumor size, tumor multiple, the number of lymph node metastases in the central region of the neck>5 and the number of lymph node metastases in the side of the neck >5 are independent risk factors for recurrence of differentiated thyroid cancer after surgical resection combined with iodine-131 and TSH inhibition therapy.

Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer

ABSTRACT Objective: The purpose of this study was to investigate the effect and influencing factors of post-surgical radioactive iodine (RAI) therapy for patients with low- and intermediate-risk differentiated thyroid cancer (DTC). Subjects and methods: A retrospective analysis of 423 low- and intermediate-risk DTC patients admitted to the Department of Nuclear Medicine, Sichuan Provincial People's Hospital from January 2005 to December 2020 was performed. All patients were treated with surgery, had a postoperative pathological diagnosis, and were treated with RAI, including 89 males and 334 females. Recurrence risk stratification: 143 cases were low-risk, and 280 cases were intermediate-risk. Results: The excellent response (ER) rate for low- and intermediate-risk were 93.7% and 78.2%, respectively (P < 0.05). There were significant differences in age, cumulative dose of [131I], and pretreatment stimulated-Tg (pre-Tg) levels between the low- and intermediate-risk groups (P < 0.05). There were significant differences in the cumulative dose of 131I and pre-Tg levels between ER and the non-ER group (P < 0.05). The area under the curve (AUC) values were 0.799 in the low-risk group, and 0.747 in the intermediate-risk group for the ROC curve by ER status of pre-Tg. The ER rate with RAI treatment decreased with an increase in pre-Tg levels. Conclusion: Pre-Tg was an important factor for RAI treatment decision-making and prognostic evaluation and differed between low-risk and intermediate-risk DTC. Aggressive RAI therapy was recommended for low-risk DTC with pre-Tg ≥ 20.0 ng/mL and in intermediate-risk group with pre-Tg ≥ 10.0 ng/mL.

Clinical efficacy and complications of surgical resection combined with 131I therapy in elderly patients with differentiated thyroid cancer / 中华地方病学杂志

Objective:To study the clinical efficacy of surgical resection combined with iodine-131 ( 131I) therapy in elderly patients with differentiated thyroid cancer and its influence on complications. Methods:Totally 82 elderly patients with differentiated thyroid cancer who were admitted to Chengde Central Hospital from March 2019 to March 2021 were selected and divided into observation group (41 cases) and control group (41 cases) according to the random number table. The control group underwent total thyroidectomy + neck lymph node dissection, and the observation group was treated with 131I after the operation on the basis of the control group. The indicators in the two groups were evaluated (postoperative observation time cutoff was 3 months), including perioperative indexes, postoperative complications, Karnofsky (KPS) score, serum levels of lymphocyte activating gene-3 (LAG-3) and recombinant human Dick-kopfx related protein-1 (DKK-1) before and after treatment, and the efficacy. Results:There was no significant difference between the two groups in the amount of intraoperative bleeding and operation time ( P > 0.05); the hospitalization time in the observation group [(6.72 ± 1.39) d] was shorter than that in the control group [(8.78 ± 1.43) d, P < 0.001]. The incidence of complications in the observation group (31.71%, 13/41) was lower than that in the control group (53.66%, 22/41, P = 0.045). After treatment, KPS scores in the two groups were higher than those before treatment ( P < 0.001); after treatment, KPS score in the observation group was higher than that in the control group ( P < 0.001). After treatment, the serum LAG-3 levels in the two groups were higher than those before treatment, while DKK-1 levels were lower than those before treatment ( P < 0.001); after treatment, the serum LAG-3 level in the observation group was higher than that in the control group, while the DKK-1 level was lower than that in the control group ( P < 0.001). The total effective rate of the observation group (95.12%, 39/41) was higher than that of the control group (80.49%, 33/41, P = 0.043). Conclusion:The clinical efficacy of surgical resection combined with 131I therapy in elderly patients with differentiated thyroid cancer is good, and it can reduce postoperative complications, up-regulate the expression of LAG-3 and down-regulate the expression of DKK-1.

Estimación de las desviaciones volumétricas de dosis entregada vs. planificada durante el tratamiento de hipertiroidismo con 131I: resultados preliminares / Estimation of volumetric dose distribution delivery deviations vs. dose planned in 131I hyperthyroidism treatment: preliminary results

Resumen En 2013, la Asociación Europea de Medicina Nuclear (AEMN) recomendó un "Procedimiento estándar" para desarrollar la dosimetría individual pretratamiento del Hipertiroidismo con 131I basada en la captación y en cinética tiroidea del paciente. Para estimar las desviaciones en la distribución de dosis entregada vs planificada al volumen tiroideo bajo este procedimiento, se desarrolló y verificó una aplicación en Matlab. Esta aplicación desarrolla el ajuste de la farmacocinética tiroidea, los cálculos de actividad acumulada, la estimación de la masa funcional tiroidea, el cálculo de la actividad a administrar para garantizar la dosis prescrita por el médico, y estimar el mapa tridimensional (3D) de dosis y los parámetros estadísticos relacionados que la caracterizan. La aplicación desarrollada se verificó empleando una imagen-maniquí y 6 farmacocinéticas conocidas. Además, se estimaron y verificaron los parámetros dosimétricos de planificación en 6 pacientes con dosis prescritas entre 150-400 Gy (promedio 241,67 Gy). Las distribuciones de actividad acumulada y de dosis absorbida fueron marcadamente heterogéneas. La distribución de dosis 3D mostró desviaciones estándar entre 18,01-27,08 % de la dosis prescrita. Las diferencias entre la dosis máxima y mínima por voxel/MBq de actividad administrada fue de 74-129 %. De acuerdo a los resultados, sólo entre el 50,2 % y 71,4 % de volumen tiroideo se tratará con la dosis prescrita ±20 %. Conclusiones: la dosis administrada al tejido tiroideo es no-homogénea y discrepa significativamente de la prescrita en algunas regiones, situación que requiere estudios posteriores más profundos con el objetivo de optimizar el tratamiento y sus resultados.

Abstract In 2013, the European Association of Nuclear Medicine Dosimetry Committee recommends a "Standard Operational Procedures for Hyperthyroidism Pre-Therapeutic Dosimetry" based on the assessment of the individual 131I uptake and kinetics. To estimate the 3D dose delivery deviations from prescribed dose during patient specific application of this SOP, a computer Matlab application was developed and verified. It was design to execute: radiopharmaceutical curve fitting, cumulated activity calculations, functional thyroid mass estimation, obtain the therapeutic planning activity to warranty the prescribed dose and produce the 3D planning dose map and related dosimetry parameters. 6 patients with 150-400Gy prescribed dose data planning (average 241,67Gy) were analysed using the developed application. The developed system was verify successfully using a test image phantom and 6 known pharmacokinetics data. The tridimensional thyroid volume cumulated activity and dose distributions were heterogeneous. 3D dose distribution showed standard deviations between 18.01-27.08 % of prescribed dose. The differences between maximum and minimum dose value per voxel/MBq were 74-129%. According to the result, between 50,2 % and 71,4 % of patient's thyroid will be treat with a dose of DP±20 % of planned dose, the rest will be overdose or sub dose. Conclusions: the 3D treatment planning dose distribution were completely no-homogenous, the significant difference observed should be study in the future more deeply in order to optimized the hyperthyroidism iodine treatment.

Design shielding assessment for a nuclear medicine service / Evaluación del diseño de blindaje de un servicio de medicina nuclear

Abstract It is recognized worldwide that the security of radioactive substances is very important and that the design of facilities where these sources are used and stored must cater for the implementation of good security measures, including the shielding of some treatment and diagnostic rooms. The radiation protection assessment of a nuclear medicine facility consists of the evaluation of the annual effective dose both to workers occupationally exposed and to members of the public. This assessment take into account the radionuclides involved, the facility features, the working procedures, the expected number of patients per year, the administered activity, the distribution of rooms, the thickness and physical materials of walls, floors and ceilings and so on. The assessment results were compared to the design requirements established by the Cuban regulatory body in order to determine whether or not, the nuclear medicine facility complies with those requirements, both for workers and for members of the public. The work presented is useful for facility designer that uses unsealed radionuclides and for the regulatory body.

Resumen A nivel mundial se reconoce que la seguridad de las sustancias radiactivas es muy importante y que el diseño de las instalaciones, donde se utilizan y almacenan las mismas, tienen que implementar medidas de seguridad adecuadas, incluyendo el blindaje de algunos locales de tratamiento y diagnóstico. La evaluación de la protección radiológica de una instalación de medicina nuclear consiste en la determinación de la dosis efectiva anual, tanto para los trabajadores ocupacionalmente expuestos a las radiaciones como para los miembros del público. Esta evaluación tuvo en consideración los radionúclidos involucrados, las características de la instalación, los procedimientos de trabajo, la cantidad de pacientes que se espera tratar o diagnosticar por año, la actividad administrada, la distribución de los locales y el espesor de los materiales empleados en las paredes, pisos y techo, entre otros. Los resultados obtenidos de la evaluación fueron comparados con los requerimientos de diseño establecidos por el órgano regulador cubano para determinar si cumplen o no con tales requerimientos para los trabajadores expuestos y miembros del público. El trabajo presentado resulta útil para diseñadores de instalaciones que utilizan sustancias abiertas y para el órgano regulador.

Graves' Disease Patients with Large Goiters Respond Best to Radioactive Iodine Doses of at Least 15 mCi: a Sonographic Volumetric Study

BACKGROUND AND OBJECTIVES: Radioactive iodine therapy (RAI) is an important treatment modality of Graves' disease (GD), but there is still not a consensus on the optimal dosage regimen. We studied the treatment success rate of different RAI doses, and examined which clinical markers were useful for determining the optimal RAI dosage for successful therapy in Korean patients. MATERIALS AND METHODS: We retrospectively studied 123 patients with GD treated with RAI between 2004 and 2014 at Chonnam National University Hwasun Hospital. The responder group was defined as patients who developed hypothyroidism requiring levothyroxine replacement following RAI, regardless of the RAI dosage. RESULTS: A total of 54 patients (43.9%) became hypothyroid after the first dose, and 31 needed two to four additional doses to achieve hypothyroidism. In the responder group as a whole (85 patients), the mean total dose of RAI was 15.5±7.0 mCi and the mean thyroid volume (TV) was 35.4±23.4 mL. When divided into low dose ( < 15 mCi, n=46) and high dose (≥15 mCi, n=39) responder groups, TV was significantly lower in the low-dose responder group (25.7±11.4 vs. 48.4±31.3, p < 0.001). The optimal cut-off TV for the low-dose responder group was < 32.37 mL (sensitivity 80.9%, specificity 76.7%). CONCLUSION: TV had significant effects on the outcome of RAI in GD patients. The optimal fixed RAI dose for Korean GD patients with a large goiter (≥33 mL) should be at least 15 mCi to achieve the best outcome.

Comparison of Radioactive Counts between a New Type of Double-tube and a Traditional Singletube Standard Source Load Model, and Their Impacts on Thyroid Iodine-131 Uptake Rates / 中国医科大学学报

Objective A new type of double-tube standard source load model provides better simulation of the human thyroid than does a traditional single-tube standard source load model. The radioactive counts of these two models were compared, as were their impacts on thyroid iodine-131 (13lI) uptake rates. Methods A double-tube standard source load model was used to analyze its impact on the rates of 131I uptake by the subjects' thyroid glands, and to compare the results with those obtained using a single-tube standard source load model. Radioactive counts in different positions were measured by thyroid function instruments, and compared. Results The 131I uptake rates by the subjects' thyroid glands at 2, 4, and 24 hours obtained using a double-tube standard source load model were lower than those obtained using a single-tube standard source load model; the differences were statistically significant (P ＜ 0. 05). Radioactive counts obtained using the double-tube standard source load model in different positions were higher than those obtained with the single-tube standard source load model; the differences were statistically significant (P ＜ 0. 05). Radioactive counts decreased with increased displacement when models were placed at 10, 12, 14, 16, and 18 cm in the horizontal direction, and at 0, 1, 2, and 3 cm in the vertical direction. Conclusion The l31I uptake rates by the subjects' thyroid glands observed using a double-tube standard source load model were lower than those observed using a single-tube standard source load model.

Current Consensus on I-131 MIBG Therapy / 대한핵의학회잡지

Metaiodobenzylguanidine (MIBG) is structurally similar to the neurotransmitter norepinephrine and specifically targets neuroendocrine cells including some neuroendocrine tumors. Iodine-131 (I-131)-labeled MIBG (I-131 MIBG) therapy for neuroendocrine tumors has been performed for more than a quarter-century. The indications of I-131 MIBG therapy include treatment-resistant neuroblastoma (NB), unresectable or metastatic pheochromocytoma (PC) and paraganglioma (PG), unresectable or metastatic carcinoid tumors, and unresectable or metastatic medullary thyroid cancer (MTC). I-131 MIBG therapy is one of the considerable effective treatments in patients with advanced NB, PC, and PG. On the other hand, I-131 MIBG therapy is an alternative method after more effective novel therapies are used such as radiolabeled somatostatin analogs and tyrosine kinase inhibitors in patients with advanced carcinoid tumors and MTC. No-carrier-aided (NCA) I-131 MIBG has more favorable potential compared to the conventional I-131 MIBG. Astatine-211-labeled meta-astatobenzylguanidine (At-211 MABG) has massive potential in patients with neuroendocrine tumors. Further studies about the therapeutic protocols of I-131 MIBG including NCA I-131 MIBG in the clinical setting and At-211 MABG in both the preclinical and clinical settings are needed.

Evaluación por Monte Carlo de los métodos de corrección de dispersión con empleando colimador pinhole / Monte Carlo evaluation of scattering correction methods in studies using pinhole collimator

La dispersión es un efecto significativo a corregir para la cuantificación de actividad. El objetivo del trabajo fue estimar la influencia de la dispersión en estudios de tiroides con 131I y colimador pinhole (5 mm) empleando el método de Monte Carlo (MC) y evaluar la eficacia de los métodos de corrección de múltiples ventanas en este tipo de estudios. Para simular la geometría de la cámara gamma y el estudio de tiroides se utilizó el código de Monte Carlo GAMOS. Para validar la geometría del cabezal se simuló y verificó experimentalmente un maniquí de tiroides, comparando la sensibilidad estimada con la medida, experimentalmente en agua y aire. Para evaluar la influencia de la dispersión a escala clínica se simularon diferentes tamaños de tiroides y profundidades del tejido, se estimaron y compararon los resultados de los métodos de Triple Ventana, Doble Ventana y Doble Ventana Reducida. Se calcularon las diferencias relativas al valor de referencia obtenido por MC. La geometría modelada fue verificada y validada. La contribución de la dispersión a la imagen fue significativa y se ubicóentre el 27 y 40 % a escala no clínica. Las discrepancias de los resultados de los diferentes métodos de corrección de dispersión a escala clínica fueron significativas (p>95 %) y estuvieron en el rango entre 9 y 86 %. El método de mejores resultados fue el de la Doble Ventana Reducida (15 %) que mostró discrepancias entre 9 y 16 %. Se concluyó que el método de la Doble Ventana Reducida (15 %) fue el más eficiente de los estudiados

Scattering is quite important for image activity quantification. In order to study the scattering factors and the efficacy of 3 multiple window energy scatter correction methods during 131I thyroid studies with a pinhole collimator (5 mm hole) a Monte Carlo simulation (MC) was developed. The GAMOS MC code was used to model the gamma camera and the thyroid source geometry. First, to validate the MC gamma camera pinhole-source model, sensibility in air and water of the simulated and measured thyroid phantom geometries were compared. Next, simulations to investigate scattering and the result of triple energy (TEW), Double energy (DW) and Reduced double (RDW) energy windows correction methods were performed for different thyroid sizes and depth thicknesses. The relative discrepancies to MC real event were evaluated. Results: The accuracy of the GAMOS MC model was verified and validated. The image’s scattering contribution was significant, between 27-40 %. The discrepancies between 3 multiple window energy correction method results were significant (between 9-86 %). The Reduce Double Window methods (15%) provide discrepancies of 9-16 %. Conclusions: For the simulated thyroid geometry with pinhole, the RDW (15 %) was the most effective

Obtención combinada de parámetros para la planificación dosimétrica 2D y 3D de tratamientos con en Hipertiroidismo / Combined parameters estimation for dosimetry treatment planning in Hyperthyroidism using 2D and 3D

La planificación, optimización y verificación de los tratamientos-paciente específico con fuentes abiertas de es objeto de investigación constante desde el punto de vista médico y de protección radiológica. El objetivo de este estudio fue verificar el uso combinado de varios equipos médico-nucleares para la estimación de los parámetros de biodistribución y farmacocinética necesarios para la planificación y verificación del tratamiento-paciente específico del hipertiroidismo. Para ello se estudiaron las respuestas de tres equipos médico-nucleares (Captor de Yodo, Cámara Gamma Philips Forte con colimador de pinhole, Cámara Mediso Nucline con colimadores de alta energía y propósitos generales para estudios planares y SPECT) empleando el maniquí de tiroides. Se comprobó la linealidad de la respuesta a la actividad en condiciones clínicas y se obtuvieron índices de correlación del ajuste superiores a 0,99 para actividades diagnósticas y terapéuticas. Se evaluó la concordancia de los parámetros calculados por los diferentes equipos y se encontró una discrepancia menor del 6 % para los índices de captación en actividades terapéuticas y del 1,1 % para las diagnósticas. Se estableció y verificó un protocolo que permite, con una sola administración de , desarrollar la cuantificación dosimétrica 2D y 3D para pacientes hipertiroideos, con un uso optimizado de los equipos imagenológicos

Optimization and verification of Specific Patient Treatment Planning with unsealed sources in hyperthyroidism diseases is a desirable goal from medical and radiation protection viewpoints. In order to verify the estimation of patient’s specific treatment dose and his/her related parameters, a combination of 3 different apparatus or pieces of equipment used in nuclear medicine were studied - the Iodine Probe, a Philips Forte Camera with pin-hole collimators and a Mediso Nucline with HEGP for planar and SPECT techniques- by using the typical neck phantom and sources simulating diagnosis and treatment procedure. The linear behavior on diagnostic and therapeutic activity range was verified, showing a linear correlation fitting factor > 0,99. The differences between thyroid uptake determinations in all equipment were less than 6 % for therapeutic activities and less than 1,1 % in the diagnostic range. The combined protocol to calculate all the necessary parameters for the patient treatment dose planning using 2D or 3D approach was established and verified, avoiding wasting time with gamma cameras and with only one administration of

Iodine-131 treatment of thyroid cancer cells leads to suppression of cell proliferation followed by induction of cell apoptosis and cell cycle arrest by regulation of B-cell translocation gene 2-mediated JNK/NF-kappaB pathways

Iodine-131 (131I) is widely used for the treatment of thyroid-related diseases. This study aimed to investigate the expression of p53 and BTG2 genes following 131I therapy in thyroid cancer cell line SW579 and the possible underlying mechanism. SW579 human thyroid squamous carcinoma cells were cultured and treated with 131I. They were then assessed for 131I uptake, cell viability, apoptosis, cell cycle arrest, p53 expression, and BTG2 gene expression. SW579 cells were transfected with BTG2 siRNA, p53 siRNA and siNC and were then examined for the same aforementioned parameters. When treated with a JNK inhibitor of SP600125 and 131I or with a NF-κB inhibitor of BMS-345541 and 131I, non-transfected SW579 cells were assessed in JNK/NFκB pathways. It was observed that 131I significantly inhibited cell proliferation, promoted cell apoptosis and cell cycle arrest. Both BTG2 and p53 expression were enhanced in a dose-dependent manner. An increase in cell viability by up-regulation in Bcl2 gene, a decrease in apoptosis by enhanced CDK2 gene expression and a decrease in cell cycle arrest at G0/G1 phase were also observed in SW579 cell lines transfected with silenced BTG2 gene. When treated with SP600125 and 131I, the non-transfected SW579 cell lines significantly inhibited JNK pathway, NF-κB pathway and the expression of BTG2. However, when treated with BMS-345541 and 131I, only the NF-κB pathway was suppressed. 131I suppressed cell proliferation, induced cell apoptosis, and promoted cell cycle arrest of thyroid cancer cells by up-regulating B-cell translocation gene 2-mediated activation of JNK/NF-κB pathways.

Change of IL-23/IL-17 axis in peripheral blood of patients with Graves disease treated by I or antithyroid drugs therapy / 安徽医科大学学报

Objective To detect the expression level of interleukin-17 (IL-17)/interleukin-23 (IL-23) axis in peripheral blood of patients with Graves disease (GD) before and after 131I or antithyroid drugs (ATD) treatment.Methods The study groups included 40 patients with incipient GD(GD group),20 of whom were treated by 131 I,others were treated by ATD.Forty sex and age matched healthy subjects were recruited as control group.ELISA was uesed to detect interleukin-17 (IL-17),interleukin-23 (IL-23) level before and after the treatment of the GD group and control group.Results ① The expression of IL-23,IL-17 in GD group was significantly higher than the control group(P ＜0.05);②6 months after 131I treatment,the level of serum IL-23,IL-17 were significantly lower than before (P ＜ 0.05),but still higher than the control group (P ＜ 0.05),which was not found in ATD treatment group.Conclusion IL-23/IL-17 axis may play a role in GD which may also be relevant to 131I treatment.

Drug-induced liver injury caused by iodine-131

Iodine-131 is a radioisotope that is routinely used for the treatment of differentiated thyroid cancer after total or near-total thyroidectomy. However, there is some evidence that iodine-131 can induce liver injury . Here we report a rare case of drug-induced liver injury (DILI) caused by iodine-131 in a patient with regional lymph node metastasis after total thyroidectomy. A 47-year-old woman was admitted with elevated liver enzymes and symptoms of general weakness and nausea. Ten weeks earlier she had undergone a total thyroidectomy for papillary thyroid carcinoma and had subsequently been prescribed levothyroxine to reduce the level of thyroid-stimulating hormone. Eight weeks after surgery she underwent iodine-131 ablative therapy at a dose of 100 millicuries, and subsequently presented with acute hepatitis after 10 days. To rule out all possible causative factors, abdominal ultrasonography, endoscopic ultrasonography (on the biliary tree and gall bladder), and a liver biopsy were performed. DILI caused by iodine-131 was suspected. Oral prednisolone was started at 30 mg/day, to which the patient responded well.

Influence of P53 on the radiotherapy response of hepatocellular carcinoma

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and it has a poor prognosis and few therapeutic options. Radiotherapy is one of the most effective forms of cancer treatment, and P53 protein is one of the key molecules determining how a cell responds to radiotherapy. The aim of this study was to determine the therapeutic efficacy of iodine-131 in three human HCC cell lines. METHODS: Western blotting was used to measure P53 expression. The effects of radiotherapy with iodine-131 were assessed by using the clonogenic assay to evaluate cell survival. Flow cytometry was carried out to examine the effects of iodine-131 on cell death, oxidative stress, reduced intracellular glutathione expression, the mitochondrial membrane potential, and the cell cycle. RESULTS: The P53 protein was not expressed in Hep3B2.1-7 cells, was expressed at normal levels in HepG2 cells, and was overexpressed in HuH7 cells. P53 expression in the HuH7 and HepG2 cell lines increased after internal and external irradiation with iodine-131. Irradiation induced a decrease in cell survival and led to a decrease in cell viability in all of the cell lines studied, accompanied by cell death via late apoptosis/necrosis and necrosis. Irradiation with 131-iodine induced mostly cell-cycle arrest in the G0/G1 phase. CONCLUSIONS: These results suggest that P53 plays a key role in the radiotherapy response of HCC.

Different beginning time of acid stimulation to reduce the acute damage of salivary glands after high-dose iodine-131 therapy for the post-surgery DTC patients / 重庆医学

Objective To compare different beginning time of acid simulation to reduce the acute damage of salivary glands after high-dose of iodine-131 treatment for the post-surgery patient with differentiated thyroid cancer (DTC) and screen out the optimal beginning time of acid simulation .Methods Total 309 cases of post-surgery DTC patients accept high-does ioding-131 treatment (average dose of ioding-131 :4 .28 ± 0 .43 GBq) ,and all patients was divided into three group randomly ,the beginning time of acid stimulation(vitamin C :10 mg per time ,three time a day ,lemonade:50 mL per 2 h) for each group is 2 ,12 and 24 h .Then observe the incidence and time of acute damage of salivary glands for each group .At same time ,we analyses the relation between acute dam-age of salivary glands with sex and age .Results The incidence of acute damage of salivary glands is 13 .21% (2 h) ,24 .51% (12 h) , 26 .73% (24 h)respectively ,the incidence of 2 h is lower than those of 12 h and 24 h obviously(P0 .05) .The occurrence time of acute damage of salivary glands for 84 .85% patients is between 10-24 h .And there is no difference of incidence of acute damage of salivary glands between different sex and age group .Conclusion 2 h maybe the optimal beginning time of acid simulation to reduce the acute damage salivary glands for the post-surgery DTC patients after high-dose iodine-131 treatment in this study .Sex and age are no influence to the occurrence of acute damage of salivary glands .

Analysis of hyperthyroid heart disease by treatment with iodine-131 radioisotopes / 中国基层医药

Objective To analyze the effect of iodine-131I in the treatment of patients with hyperthyroid heart disease(HHD).Methods The clinical materials and therapeutic effect by 131 I were reviewed in 100 patients with HDD.Results The heal rate of hyperthyroidism and HHD were 82.3％,86.5％ in treatment group,and were higher than that of the control group (69.0％ and 76.2％ ) ( x2 =3.80,3.83,P ＜ 0.05 ) ; HHD with atrial fibrillation was 65.0％,average cardioversion after 131I treatment was 74.4％ after the treatment by 131I;The LVEDD、LVESD、LVEDV and HR after 131 I treatment were lower compared with before treatment ( all P ＜ 0.05 ),SV and EF were increased ( all P ＜ 0.01 ).Conclusion 131I treatment in patients with HHD,can significantly improve the efficacy of a heart disease

Transient cell function disruption by low dose acute exposure of ionizing radiation.

Incubation of BMG-1 cells with thallium chloride (201Tl) in the range of diagnostic dose did not show a smooth uptake curve and appeared to have an unsuspected deviation in initial phase. In the present study this unexpected phenomenon was explored, using commonly used radionuclides (viz., 201Tl and 131I). Comparison was made with technetium-99m pertechnetate (99mTcO4-) and technetium-99m labeled methoxyisobutylisonitrile (99mTc-MIBI) that are known to show conventional 2 phase graph representing inflow and outflow segments. Serial in vitro, ex-vivo and in vivo gamma scintigraphy as well as NMR spectroscopy experiments were conducted to corroborate the results. BMG-1 cells demonstrated a four-phase uptake pattern with 201Tl as compared to a conventional biphasic pattern with 99mTc-MIBI. Flow cytometry data however did not reveal any 201Tl induced cell injury. Further, mice tissue extracts injected with 201Tl also showed a transient depression in its uptake. Scintigraphy experiments in rabbits administered with diagnostic dose of 201Tl and 131I confirmed the in vitro and ex vivo findings. Further, proton NMR spectroscopy showed decrease in the level of choline at 3 h and 24 h in 201Tl treated animals as compared to control. Phosphoethanolamine peak firstly decreased at 3 h but reached normal level at 24 h time point. No significant change was observed in the level of betaine. This transient reduction in internalization of 201Tl and 131I may represent a hitherto unknown acute effect of low dose radiation, i.e., transient depression in Na+-K+ ATPase pump activity without any apparent evidence of cell damage, representing a transient cell membrane dysfunction. The phenomenon may present a mechanistical explanation of ‘thyroid stunning’ at cellular level and suggest that it may be more universal in nature than suspected till now.

Aggressive form of thyroglossal duct cyst carcinoma: role of ablative dose of Iodine-131

Ectopic thyroid tissue carcinoma is very rare and has usually good prognosis. It could arise in 1 percent of thyroglossal duct cysts (TDC), the most common nonodontogenic cysts that occur in the neck, which results from a failure in obliterating the embryogenic duct produced during thyroid migration. TDC is most often diagnosed during the childhood but may be discovered later in adult age. In most of the cases reported in the literature, thyroid carcinoma arising in the TDC is limited to the cyst without local extension and its efficient treatment consist of the surgical removal of the cyst by Sistrunk's operation. However, some controversies remain regarding the indication of total thyroidectomy when thyroid investigations are normal. Cases of aggressive thyroid carcinomas of the TCD with metastatic cervical lymph nodes are exceptional, mainly when histological findings of the thyroid gland are normal. We report a case of an aggressive form of a thyroglossal duct cyst carcinoma complicated with several infiltrated cervical lymph nodes but normal thyroid gland. The therapeutic strategy adopted in this case shows the decisive role of the post-operative ablative dose of Iodine-131 both for treatment and staging of aggressive form of thyroid carcinoma arising in thyroglossal duct cyst.

Comparison of short-term effects between interventional embolization treatment and iodine-131 therapy for Graves' hyperthyroidism / 介入放射学杂志

Objective To compare the short-term effects between interventional arterial embolization and iodine-131 therapy in treating Graves'disease.Methods A total of 84 patients with Graves'disease (GD),confirmed by clinical data and laboratory tests,were divided into two groups:interventional group(n=42)receiving arterial embolization and iodine-131 group(n=42)receiving iodine-131 therapy.Before and after the treatment thyroid angiography and SPECT/CT imaging were performed to determine the shape and size of the thyroid,and radioimmunoassay method was used to measure serum levels of FT3,VF4,TSH and TRAb at 3.6 and 12 months after the therapy.The results were compared and statistically analyzed.The occurrence of complications was observed. Results No statistically significant difference in short-term therapeutic effects was found between interventional group and iodine-131 group.The occurrence of early severe complication was much higher in interventional group than that in iodine-131 group,while the occurrence of hypothyroidism was obviously higher in iodine-131 group than that in interventionai group.Conclusion Both interventional embolization and iodine-131 therapy have reliable effect for the treatment of Graves'disease.Iodine-131 therapy may be used in patients who plan to receive initial treatment or in patients who failed to effectively respond to other kinds of therapies,while interventional embolization may be employed in patients who are not able to receive surgery or in patients who have failed to respond to antithyroid drug treatment,or in patients whose iodine-131 intake rate is too low to undergo iodine-131 therapy,especially in patients with refractory and intractable hyperthyroidism. Interventional embolization can be regarded as an alternative treatment for Graves'disease.